Journal Article

The equine Hendra virus vaccine remains a highly effective preventative measure against infection in horses and humans: 'The imperative to develop a human vaccine for the Hendra virus in Australia'

Taylor, Melanie, Bryden, Wayne L., Plowright, Raina K., Reid, Peter A., Marsh, Glenn A., Toribio, Jenny-Ann, Fulton, Ian, Peel, Alison J., Skerratt, Lee F., Barr, Jennifer, Cunningham, Andrew A., Martin, Gerardo, Wang, Lin-Fa, Wood, James L. N., Broder, Christopher C., Smith, Ina, Dhand, Navneet, Restif, Olivier, Field, Hume E., Baker, Michelle, Breed, Andrew C., Crameri, Gary, Hayman, David T. S., Secombe, Cristy

2016

Overview

The efficacy and safety of the recombinant equine vaccine has been clearly demonstrated (4-6), and both government and industry animal health authorities strongly recommend its use as 'the single most effective way of reducing the risk of Hendra virus infection in horses' (7). [...]we express no objection to the development of a human vaccine against HeV; however, we are emphatic that Zahoor and Mudie (1) are unjustified in using viral evolution, vaccine inefficiency, and changing clinical syndromes as motivations. [...]Dr. Broder is a coinventor on U.S. Patent No. 8,865,171 and 9,045,532, with royalties paid by Zoetis, Inc., and Australian Patent No. 2005327194 Patent assignees are the United States of America as represented by the Department of Health and Human Services (Washington DC) and the Henry M. Jackson Foundation (Bethesda, MD).

• Publisher: Taylor & Francis,Taylor & Francis Ltd,Co-Action Publishing
• Subject: Chiroptera / Encephalitis / Genomes / Horses / Infections / Laboratory animals / Letter to the Editor / Paramyxoviridae / Scholarships & fellowships / Vaccines / Viruses